Johnson & Johnson (NYSE:JNJ) Shares Sold by Ridgecrest Wealth Partners LLC

Ridgecrest Wealth Partners LLC trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 7.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 13,293 shares of the company’s stock after selling 1,052 shares during the period. Johnson & Johnson comprises approximately 1.0% of Ridgecrest Wealth Partners LLC’s investment portfolio, making the stock its 18th biggest position. Ridgecrest Wealth Partners LLC’s holdings in Johnson & Johnson were worth $1,922,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of JNJ. IFS Advisors LLC lifted its position in shares of Johnson & Johnson by 138.9% in the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after acquiring an additional 100 shares in the last quarter. Highline Wealth Partners LLC purchased a new stake in shares of Johnson & Johnson in the third quarter valued at $31,000. RPg Family Wealth Advisory LLC acquired a new stake in shares of Johnson & Johnson in the third quarter worth $35,000. Mowery & Schoenfeld Wealth Management LLC raised its position in Johnson & Johnson by 58.7% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock valued at $40,000 after buying an additional 91 shares during the period. Finally, Activest Wealth Management purchased a new stake in Johnson & Johnson in the 3rd quarter worth about $40,000. Institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling

In related news, Director Mark A. Weinberger acquired 1,000 shares of the company’s stock in a transaction dated Thursday, December 12th. The shares were bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $152.78 on Friday. The firm has a market capitalization of $367.82 billion, a PE ratio of 22.97, a PEG ratio of 2.45 and a beta of 0.51. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The firm’s fifty day simple moving average is $147.73 and its 200 day simple moving average is $156.10.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The business had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same period in the previous year, the company posted $2.29 earnings per share. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.56 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.25%. Johnson & Johnson’s payout ratio is 74.59%.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on JNJ. Bank of America dropped their target price on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating on the stock in a report on Thursday, January 23rd. Stifel Nicolaus dropped their price objective on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research note on Thursday, January 23rd. Wells Fargo & Company lowered their price target on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a report on Thursday, January 23rd. Morgan Stanley cut their price objective on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Finally, Wolfe Research initiated coverage on Johnson & Johnson in a research note on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price on the stock. Nine equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $170.44.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.